# Katja Rohwedder

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/katja-rohwedder/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,060 |
| Field | Diabetes Treatment and Management |
| h-index | 16 |
| i10-index | 28 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5038617498 |
| Works | 132 |

## Researcher papers

Showing 12 of 13.

- [Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin](https://scholariq.org/papers/dapagliflozin-versus-glipizide-as-add-on-therapy-in-patients-with-type-2/)
- [Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years](https://scholariq.org/papers/dapagliflozin-in-patients-with-type-2-diabetes-receiving-high-doses-of-insulin/)
- [Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data](https://scholariq.org/papers/long-term-glycaemic-response-and-tolerability-of-dapagliflozin-versus-a/)
- [Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial](https://scholariq.org/papers/dapagliflozin-improves-glycemic-control-and-reduces-body-weight-as-add-on/)
- [Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin](https://scholariq.org/papers/durability-of-glycaemic-efficacy-over-2-years-with-dapagliflozin-versus/)
- [Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes](https://scholariq.org/papers/impact-of-finerenone-induced-albuminuria-reduction-on-chronic-kidney-disease/)
- [Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes](https://scholariq.org/papers/efficacy-and-safety-of-dapagliflozin-or-dapagliflozin-plus-saxagliptin-versus/)
- [Durability and tolerability of dapagliflozin over 52 weeks as add‐on to metformin and sulphonylurea in type 2 diabetes](https://scholariq.org/papers/durability-and-tolerability-of-dapagliflozin-over-52-weeks-as-add-on-to/)
- [Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes](https://scholariq.org/papers/dapagliflozin-effects-on-haematocrit-red-blood-cell-count-and-reticulocytes-in/)
- [Finerenone in Patients With a Recent Worsening Heart Failure Event](https://scholariq.org/papers/finerenone-in-patients-with-a-recent-worsening-heart-failure-event/)
- [Efficacy and Safety of the Kidney Function–Based Finerenone Dosing Strategy Used in FINEARTS-HF](https://scholariq.org/papers/efficacy-and-safety-of-the-kidney-function-based-finerenone-dosing-strategy-used/)
- [Finerenone and eGFR Slope across Different Levels of Baseline Albuminuria and eGFR](https://scholariq.org/papers/finerenone-and-egfr-slope-across-different-levels-of-baseline-albuminuria-and/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)
- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.